Abstract

Planar supported lipid bilayers (PSLBs) presenting T cell receptor (TCR) ligands and ICAM-1 induce budding of extracellular microvesicles enriched in functional TCR, defined here as synaptic ectosomes (SE), from helper T cells. SE bind peptide-MHC directly exporting TCR into the synaptic cleft, but incorporation of other effectors is unknown. Here, we utilized bead supported lipid bilayers (BSLB) to capture SE from single immunological synapses (IS), determined SE composition by immunofluorescence flow cytometry and enriched SE for proteomic analysis by particle sorting. We demonstrate selective enrichment of CD40L and ICOS in SE in response to addition of CD40 and ICOSL, respectively, to SLB presenting TCR ligands and ICAM-1. SE are enriched in tetraspanins, BST-2, TCR signalling and ESCRT proteins. Super-resolution microscopy demonstrated that CD40L is present in microclusters within CD81 defined SE that are spatially segregated from TCR/ICOS/BST-2. CD40L+ SE retain the capacity to induce dendritic cell maturation and cytokine production.

Data availability

The Mass spec data set has been deposited in ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD007988.

The following data sets were generated

Article and author information

Author details

  1. David George Saliba

    Kennedy Institute of Rheumatology, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  2. Pablo F Cespedes-Donoso

    Kennedy Institute of Rheumatology, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1641-4107
  3. Štefan Bálint

    Kennedy Institute of Rheumatology, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4470-5881
  4. Ewoud B Compeer

    Kennedy Institute of Rheumatology, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3050-7633
  5. Kseniya Korobchevskaya

    Kennedy Institute of Rheumatology, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  6. Salvatore Valvo

    Kennedy Institute of Rheumatology, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  7. Viveka Mayya

    Kennedy Institute of Rheumatology, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  8. Audun Kvalvaag

    Kennedy Institute of Rheumatology, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  9. Yanchun Peng

    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  10. Tao Dong

    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3545-3758
  11. Maria-Laura Tognoli

    Department of Oncology, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  12. Eric O'Neill

    Department of Oncology, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  13. Sarah Bonham

    Discovery Proteomics Facility, Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  14. Roman Fischer

    Discovery Proteomics Facility, Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9715-5951
  15. Benedikt M Kessler

    Discovery Proteomics Facility, Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  16. Michael L Dustin

    Kennedy Institute of Rheumatology, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
    For correspondence
    michael.dustin@kennedy.ox.ac.uk
    Competing interests
    Michael L Dustin, Reviewing editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4983-6389

Funding

European Commission (AdG 670930)

  • David George Saliba
  • Pablo F Cespedes-Donoso
  • Štefan Bálint
  • Ewoud B Compeer
  • Michael L Dustin

Wellcome (PRF 100262)

  • Michael L Dustin

Cancer Research UK (UK A19277)

  • Eric O'Neill

Chinese Academy of Sciences (2018-I2M-2-002)

  • Yanchun Peng
  • Tao Dong

National Institutes of Health (N/A)

  • Michael L Dustin

Kennedy Trust for Rheumatology Research (N/A)

  • Michael L Dustin

European Molecular Biology Organization (ALTF 1420-2015)

  • Pablo F Cespedes-Donoso

The Research Council of Norway in conjunction with Marie Sklodowska-Curie Actions (275466)

  • Audun Kvalvaag

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Leukapheresis products (non-clinical and de-identified) from donor blood were used as a source of human T cells and monocytes. The Non-Clinical Issue division of National Health Service approved the use of leukapheresis reduction (LRS) chambers products at the University of Oxford (REC 11/H0711/7). Clone 35 was isolated from a healthy volunteer where written informed consent was given. Ethical approval was obtained from the University of Oxford Tropical Ethics Committee (OXTREC).

Reviewing Editor

  1. Facundo D Batista, Ragon Institute of MGH, MIT and Harvard, United States

Version history

  1. Received: April 9, 2019
  2. Accepted: August 28, 2019
  3. Accepted Manuscript published: August 30, 2019 (version 1)
  4. Version of Record published: September 17, 2019 (version 2)

Copyright

© 2019, Saliba et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,269
    Page views
  • 619
    Downloads
  • 50
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. David George Saliba
  2. Pablo F Cespedes-Donoso
  3. Štefan Bálint
  4. Ewoud B Compeer
  5. Kseniya Korobchevskaya
  6. Salvatore Valvo
  7. Viveka Mayya
  8. Audun Kvalvaag
  9. Yanchun Peng
  10. Tao Dong
  11. Maria-Laura Tognoli
  12. Eric O'Neill
  13. Sarah Bonham
  14. Roman Fischer
  15. Benedikt M Kessler
  16. Michael L Dustin
(2019)
Composition and structure of synaptic ectosomes exporting antigen receptor linked to functional CD40 ligand from helper T-cells
eLife 8:e47528.
https://doi.org/10.7554/eLife.47528

Share this article

https://doi.org/10.7554/eLife.47528

Further reading

    1. Cell Biology
    2. Immunology and Inflammation
    Jasper Iske, Rachid El Fatimy ... Abdallah Elkhal
    Research Article

    Septic shock is characterized by an excessive inflammatory response depicted in a cytokine storm that results from invasive bacterial, fungi, protozoa, and viral infections. Non-canonical inflammasome activation is crucial in the development of septic shock promoting pyroptosis and proinflammatory cytokine production via caspase-11 and gasdermin D (GSDMD). Here, we show that NAD+ treatment protected mice toward bacterial and lipopolysaccharide (LPS)-induced endotoxic shock by blocking the non-canonical inflammasome specifically. NAD+ administration impeded systemic IL-1β and IL-18 production and GSDMD-mediated pyroptosis of macrophages via the IFN-β/STAT-1 signaling machinery. More importantly, NAD+ administration not only improved casp-11 KO (knockout) survival but rendered wild type (WT) mice completely resistant to septic shock via the IL-10 signaling pathway that was independent from the non-canonical inflammasome. Here, we delineated a two-sided effect of NAD+ blocking septic shock through a specific inhibition of the non-canonical inflammasome and promoting immune homeostasis via IL-10, underscoring its unique therapeutic potential.

    1. Immunology and Inflammation
    2. Structural Biology and Molecular Biophysics
    Ana C Chang-Gonzalez, Robert J Mallis ... Wonmuk Hwang
    Research Article Updated

    Mechanical force is critical for the interaction between an αβ T cell receptor (TCR) and a peptide-bound major histocompatibility complex (pMHC) molecule to initiate productive T-cell activation. However, the underlying mechanism remains unclear. We use all-atom molecular dynamics simulations to examine the A6 TCR bound to HLA-A*02:01 presenting agonist or antagonist peptides under different extensions to simulate the effects of applied load on the complex, elucidating their divergent biological responses. We found that TCR α and β chains move asymmetrically, which impacts the interface with pMHC, in particular the peptide-sensing CDR3 loops. For the wild-type agonist, the complex stabilizes in a load-dependent manner while antagonists destabilize it. Simulations of the Cβ FG-loop deletion, which reduces the catch bond response, and simulations with in silico mutant peptides further support the observed behaviors. The present results highlight the combined role of interdomain motion, fluctuating forces, and interfacial contacts in determining the mechanical response and fine peptide discrimination by a TCR, thereby resolving the conundrum of nearly identical crystal structures of TCRαβ-pMHC agonist and antagonist complexes.